Literature DB >> 18770030

Lactacystin stimulates stellation of cultured rat cortical astrocytes.

Qing-Guo Ren1, Ying Yu, Deng-Ji Pan, Xiang Luo, Xue-Zhen Wang, Wei Wang.   

Abstract

Proteasome inhibition has been observed in many neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Here, the effect of proteasome inhibition on the morphology of cultured rat cortical astrocytes was investigated. Increasing evidence suggests that the function of astrocytes is related closely to its morphology. Lactacystin, a specific inhibitor of the 20S proteasome, can induce astrocytes stellation in a dose dependent manner and reorganize the cytoskeleton of astrocytes. Furthermore, decreased levels of expression of Rho A, total Akt, and Phospho-Akt were found in the process of astrocytes stellation and lysophosphatidic acid, an activator of Rho A, can largely reverse the astrocytes stellation caused by lactacystin. This suggests that proteasome inhibition in astrocytes could stabilize signals of morphological changes that might be processed through Rho and Akt signaling cascade. Our results suggest that proteasome inhibition might function as a factor regulating astrocytes morphology in some pathophysiological conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18770030     DOI: 10.1007/s11064-008-9830-6

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  42 in total

1.  N-myc and c-myc expression in Alzheimer disease, Huntington disease and Parkinson disease.

Authors:  I Ferrer; R Blanco
Journal:  Brain Res Mol Brain Res       Date:  2000-05-05

2.  Evidence that protease-activated receptor-2 mediates trypsin-induced reversal of stellation in cultured rat astrocytes.

Authors:  Gyu Hwan Park; Jae Ryun Ryu; Chan Young Shin; Min Sik Choi; Byoung-Hee Han; Won-Ki Kim; Hyoung-Chun Kim; Kwang Ho Ko
Journal:  Neurosci Res       Date:  2005-10-26       Impact factor: 3.304

3.  Effects of tau phosphorylation on proteasome activity.

Authors:  Qing-Guo Ren; Xiao-Mei Liao; Xiao-Qian Chen; Gong-Ping Liu; Jian-Zhi Wang
Journal:  FEBS Lett       Date:  2007-03-05       Impact factor: 4.124

Review 4.  Astrocyte dysfunction in neurological disorders: a molecular perspective.

Authors:  Gerald Seifert; Karl Schilling; Christian Steinhäuser
Journal:  Nat Rev Neurosci       Date:  2006-03       Impact factor: 34.870

5.  Soman-induced seizures rapidly activate astrocytes and microglia in discrete brain regions.

Authors:  L A Zimmer; M Ennis; M T Shipley
Journal:  J Comp Neurol       Date:  1997-02-24       Impact factor: 3.215

6.  Dynamic reorganization of the astrocyte actin cytoskeleton elicited by cAMP and PACAP: a role for phosphatidylInositol 3-kinase inhibition.

Authors:  Virgili Perez; Tristan Bouschet; Céline Fernandez; Joël Bockaert; Laurent Journot
Journal:  Eur J Neurosci       Date:  2005-01       Impact factor: 3.386

7.  Statins induce differentiation and cell death in neurons and astroglia.

Authors:  Pia März; Uwe Otten; André R Miserez
Journal:  Glia       Date:  2007-01-01       Impact factor: 7.452

8.  Impaired proteasome function in Alzheimer's disease.

Authors:  J N Keller; K B Hanni; W R Markesbery
Journal:  J Neurochem       Date:  2000-07       Impact factor: 5.372

9.  Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias).

Authors:  A Barbeau
Journal:  Neurotoxicology       Date:  1984       Impact factor: 4.294

10.  Characterization of chronic low-level proteasome inhibition on neural homeostasis.

Authors:  Qunxing Ding; Edgardo Dimayuga; Sarah Martin; Annadora J Bruce-Keller; Vidya Nukala; Ana Maria Cuervo; Jeffrey N Keller
Journal:  J Neurochem       Date:  2003-07       Impact factor: 5.372

View more
  1 in total

1.  Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease.

Authors:  Anthony C Vernon; William R Crum; Saga M Johansson; Michel Modo
Journal:  PLoS One       Date:  2011-02-25       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.